Miras-Mirakian P, Claustrat F, Dechaud H, Pugeat M
Laboratoire de la Clinique endocrinologique, Hôpital de l'Antiquaille, Lyon.
J Gynecol Obstet Biol Reprod (Paris). 1992;21(4):419-23.
We have studied the response of prolactin (PRL) secretion to the test combining i.m. sulpiride in the dose 1 mg/kg followed by 200 micrograms i.v. of TRH, in 12 normal women and 37 patients with hyperprolactinaemia. The response was expressed as a percentage rise in plasma PRL concentration (delta %) 20 minutes after the administration of sulpiride or TRH. In the controls the response in PRL secretion to sulpiride worked out at between 639 and 2,760%. When there was a pituitary adenoma or supra-sellar lesion the PRL response to sulpiride was always less than 481%. On the other hand the PRL response with TRH after sulpiride was not significantly different as between the controls (less than 175%) and the patients (less than 91%). We conclude: 1) the combined sulpiride and TRH test is useless for assessing hyperprolactinaemia; 2) the sulpiride test on the other hand makes it possible to show that hyperprolactinaemia cannot be stimulated and to suspect the presence in this case of a prolactin producing adenoma or a supra-sellar tumour.
我们对12名正常女性和37名高催乳素血症患者进行了研究,采用肌肉注射1毫克/千克舒必利,随后静脉注射200微克促甲状腺激素释放激素(TRH)的联合试验,以观察催乳素(PRL)分泌的反应。反应以舒必利或TRH给药后20分钟血浆PRL浓度升高的百分比(δ%)表示。在对照组中,PRL分泌对舒必利的反应为639%至2760%。当存在垂体腺瘤或鞍上病变时,PRL对舒必利的反应始终低于481%。另一方面,舒必利后TRH引起的PRL反应在对照组(低于175%)和患者组(低于91%)之间无显著差异。我们得出结论:1)舒必利与TRH联合试验对评估高催乳素血症无用;2)另一方面,舒必利试验能够表明高催乳素血症无法被刺激,并怀疑在这种情况下存在催乳素分泌腺瘤或鞍上肿瘤。